SEEK ID: https://seek.lisym.org/people/99
Location: Germany
ORCID: Not specified
Joined: 24th Apr 2018
Expertise: Not specified
Tools: Not specified
Related items
- Programmes (2)
- Projects (5)
- Institutions (1)
- Investigations (1+1)
- Studies (1+1)
- Assays (3+1)
- Publications (17)
- Presentations (1+2)
- Documents (0+1)
LiSyM-Krebs ist ein nationales Forschungsnetz zur Früherkennung und Prävention von Leberkrebs, das unter Verwendung des systemmedizinischen Forschungsansatzes die komplexen, dynamischen Prozesse der Krankheitsprogression analysiert, um ausgehend von den Erkenntnissen aus dem Forschungsnetz LiSyM die Entstehung von Leberkrebs besser zu verstehen, vorherzusagen und im besten Fall sogar zu verhindern. LiSyM-Krebs setzt die erfolgreichen Forschungsaktivitäten der BMBF-Vorgängerprogramme ...
Projects: LiSyM-Krebs Partnering, Forschungsnetzwerk LiSyM-Krebs, SMART-NAFLD, DEEP-HCC network, C-TIP-HCC network
Web page: https://www.lisym-cancer.org
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
Forschungsnetzwerk zur Früherkennung und Prävention- LiSyM-Krebs
Ein Netzwerk von Klinikern, Wissenschaftlern und Datenmanagern hat sich zur Aufgabe gemacht, Methoden zu entwickeln, um Patienten mit einem hohen Risiko für ein Leberkarzinom frühzeitig, in Vorstadien der Tumorentwicklung, identifizieren zu können. Gemeinsam bilden sie das „Systemmedizinische Forschungsnetzwerk zur Früherkennung und Prävention von Leberkrebs“, LiSym-Krebs, das vom Bundesministerium für Bildung und Forschung ...
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: Not specified
Organisms: Homo sapiens, Mus musculus, Rattus norvegicus, Rattus rattus
DEEP-HCC - Detailed Analysis of the Spatial Organization of the Development of Hepatocellular Carcinoma
Programme: LiSyM-Krebs - Systemmedizinisches Forschungsnetz zur Früherkennung und Prävention von Leberkrebs
Public web page: Not specified
Organisms: Homo sapiens, Mus musculus
This comprises the whole LiSyM network
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org
Start date: 1st Jan 2016
Organisms: Rattus norvegicus, Rattus rattus, Mus musculus, Homo sapiens
One of the tasks of the healthy liver is to store fat. Yet, at some stage, too much fat makes the liver sick. One critical time point occurs when a healthy fatty liver becomes inflamed and progresses to steatohepatitis, or NASH. LiSyM-Pillar I will identify what events lead to this transition. Does it occur in all parts of the liver? Which molecules indicate that it is taking place? Can the degeneration be stopped or undone - and if so, how?
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research/zones-of-the-liver
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
Day-to-day science within the LiSyM is overseen and directed by the the LiSyM Scientific Leadership Team. This coordination team comprises the pillar coordinators and additional LiSyM members, and ensures smooth interaction between multi-skilled groups, often working in different institutions and across significant distances within Germany.
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/who-we-are
Organisms: Not specified
We apply multiphoton imaging, 3D digital reconstructions and computational simulations to generate spatially-resolved geometrical and functional models of human liver tissue at different stages of non-alcoholic fatty liver disease (NAFLD).
Submitter: Fabian Segovia Miranda
Studies: Generation of 3D spatially resolved geometrical and functional models of...
Assays: Experimental assay NAFLD/HO, Experimental assay NAFLD/NC, Experimental assay NAFLD/STEA, Experimental assay NAFLD/eNASH
Snapshots: No snapshots
Histopathological analysis of human biopsies. To quantitatively characterize the transition from simple STEA to eNASH, we stained, imaged and digitally reconstructed human liver tissue in 2D and 3D from biopsies of 25 patients classified into four groups: normal control (NC, n = 6), healthy obese (HO, n = 4), steatosis (STEA, n = 8) and eNASH (n = 7).
Submitter: Fabian Segovia Miranda
Investigation: Three-dimensional spatially resolved geometrica...
Assays: Experimental assay NAFLD/HO, Experimental assay NAFLD/NC, Experimental assay NAFLD/STEA, Experimental assay NAFLD/eNASH
Snapshots: No snapshots
Experimental assay Human-NAFLD/HO , 4 biopsies from healthy obese patients. Samples for the HO category were obtained in patients undergoing bariatric surgery with a BMI > 30 and subgroups defined by liver histology as follows: HO samples showed a normal liver histology such as the NC samples.
-h692a -h6758 -h6922 -h7230
Files can be opened and visualised with http://motiontracking.mpi-cbg.de/get/ software
Submitter: Fabian Segovia Miranda
Assay type: Experimental Assay Type
Technology type: Technology Type
Investigation: Three-dimensional spatially resolved geometrica...
Organisms: No organisms
SOPs: No SOPs
Data files: Patient characteristics by group
Snapshots: No snapshots
Experimental assay Human-NAFLD/NC 6 biopsies from normal control patients. : NC samples showed steatosis ≤5%, no inflammation, no ballooning and no fibrosis and were obtained during liver resections or biopsy in non-hepatobiliary malignancy in patients with a BMI<30kg/m2. Livers were either free of metastases or a distance of at least 2 cm to the next metastasis observed.
Image data for this assay available via link to file folder containing ...
Submitter: Fabian Segovia Miranda
Assay type: Image Collection
Technology type: Technology Type
Investigation: Three-dimensional spatially resolved geometrica...
Organisms: No organisms
SOPs: No SOPs
Data files: Patient characteristics by group
Snapshots: No snapshots
Experimental assay Human-NAFLD/eNASH Samples for the eNASH category were obtained in patients undergoing bariatric surgery with a BMI > 30 and subgroups defined by liver histology as follows: eNASH samples were characterized by >5% fat, an inflammation grade of at least 1, fibrosis ≤1 and ballooning ≤1.
Image data for this assay available via link to file folder containing image data for listed patient IDs (patientID in a file name) ...
Submitter: Olga Krebs
Assay type: Experimental Assay Type
Technology type: Technology Type
Investigation: Three-dimensional spatially resolved geometrica...
Organisms: No organisms
SOPs: No SOPs
Data files: Patient characteristics by group
Snapshots: No snapshots
Abstract (Expand)
Authors: C. Mayer, S. Nehring, M. Kucken, U. Repnik, S. Seifert, A. Sljukic, J. Delpierre, H. Morales-Navarrete, S. Hinz, M. Brosch, B. Chung, T. Karlsen, M. Huch, Y. Kalaidzidis, L. Brusch, J. Hampe, C. Schafmayer, M. Zerial
Date Published: 31st Jul 2023
Publication Type: Journal
PubMed ID: 37522754
Citation: EMBO Rep. 2023 Jul 31:e57181. doi: 10.15252/embr.202357181.
Abstract (Expand)
Authors: Maarten P. Bebelman, Matthew J. Bovyn, Carlotta M. Mayer, Julien Delpierre, Ronald Naumann, Nuno P. Martins, Alf Honigmann, Yannis Kalaidzidis, Pierre A. Haas, Marino Zerial
Date Published: 3rd Apr 2023
Publication Type: Journal
Citation: Journal of Cell Biology 222(4),e202208002
Abstract
Authors: Lenka Belicova, Urska Repnik, Julien Delpierre, Elzbieta Gralinska, Sarah Seifert, José Ignacio Valenzuela, Hernán Andrés Morales-Navarrete, Christian Franke, Helin Räägel, Evgeniya Shcherbinina, Tatiana Prikazchikova, Victor Koteliansky, Martin Vingron, Yannis L. Kalaidzidis, Timofei Zatsepin, Marino Zerial
Date Published: 4th Oct 2021
Publication Type: Journal
Citation: Journal of Cell Biology 220(10),e202103003
Abstract (Expand)
Authors: Lenka Belicova, Urska Repnik, Julien Delpierre, Elzbieta Gralinska, Sarah Seifert, José Ignacio Valenzuela, Hernán Andrés Morales-Navarrete, Christian Franke, Helin Räägel, Evgeniya Shcherbinina, Tatiana Prikazchikova, Victor Koteliansky, Martin Vingron, Yannis Kalaidzidis, Timofei Zatsepin, Marino Zerial
Date Published: 2021
Publication Type: Unpublished
DOI: 10.1101/2020.12.31.424978
Citation: biorxiv;2020.12.31.424978v2,[Preprint]
Abstract (Expand)
Authors: A. Scholich, S. Syga, H. Morales-Navarrete, F. Segovia-Miranda, H. Nonaka, K. Meyer, W. de Back, L. Brusch, Y. Kalaidzidis, M. Zerial, F. Julicher, B. M. Friedrich
Date Published: 11th Dec 2020
Publication Type: Journal
PubMed ID: 33301446
Citation: PLoS Comput Biol. 2020 Dec 10;16(12):e1008412. doi: 10.1371/journal.pcbi.1008412. eCollection 2020 Dec.
Talk at the Jamboree 2021 about epigenomic map of human liver zonation and loss of zonation in end-stage liver disease
Creators: Mario Brosch, Jochen Hampe, Lutz Brusch, Marino Zerial, Clemens Schafmayer
Submitter: Mario Brosch